Novel Pyrazino[2,3-b] Pyrazines as mTOR Kinase Inhibitors for Treating Cancer and other Diseases


Cite item

Full Text

Abstract

:This paper describes the synthesis of some heteroaryl compounds and compositions comprising an effective amount of one or more such compounds and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway, comprising administering an adequate amount of a heteroaryl compound to a patient in need thereof. These compounds are mTOR/PI3K/Akt pathway inhibitors.

About the authors

Surya De

Department of Chemistry, Conju-Probe

Author for correspondence.
Email: info@benthamscience.net

References

  1. Wullschleger, S.; Loewith, R.; Hall, M.N. TOR signaling in growth and metabolism. Cell, 2006, 124(3), 471-484. doi: 10.1016/j.cell.2006.01.016 PMID: 16469695
  2. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307(5712), 1098-1101. doi: 10.1126/science.1106148 PMID: 15718470
  3. Xu, K.; Liu, P.; Wei, W. mTOR signaling in tumorigenesis. Biochim. Biophys. Acta Rev. Cancer, 2014, 1846(2), 638-654. doi: 10.1016/j.bbcan.2014.10.007 PMID: 25450580
  4. Easton, J.B.; Houghton, P.J. mTOR and cancer therapy. Oncogene, 2006, 25(48), 6436-6446. doi: 10.1038/sj.onc.1209886 PMID: 17041628
  5. Zoncu, R.; Efeyan, A.; Sabatini, D.M. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol., 2011, 12(1), 21-35. doi: 10.1038/nrm3025 PMID: 21157483
  6. Canaud, G.; Bienaimé, F.; Tabarin, F.; Bataillon, G.; Seilhean, D.; Noël, L.H.; Dragon-Durey, M.A.; Snanoudj, R.; Friedlander, G.; Halbwachs-Mecarelli, L.; Legendre, C.; Terzi, F. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N. Engl. J. Med., 2014, 371(4), 303-312. doi: 10.1056/NEJMoa1312890 PMID: 25054716
  7. Georgakis, G.V.; Younes, A. From Rapa Nui to rapamycin: Targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev. Anticancer Ther., 2006, 6(1), 131-140. doi: 10.1586/14737140.6.1.131 PMID: 16375650
  8. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 2002, 1(4), 309-315. doi: 10.1038/nrd773 PMID: 12120282
  9. Karami fath, M.; Ebrahimi, M.; Nourbakhsh, E.; Zia Hazara, A.; Mirzaei, A.; Shafieyari, S.; Salehi, A.; Hoseinzadeh, M.; Payandeh, Z.; Barati, G. PI3K/Akt/mTOR signaling pathway in cancer stem cells. Pathol. Res. Pract., 2022, 237, 154010. doi: 10.1016/j.prp.2022.154010 PMID: 35843034
  10. Luo, Q.; Du, R.; Liu, W.; Huang, G.; Dong, Z.; Li, X. PI3K/Akt/mTOR signaling pathway: Role in esophageal squamous cell carcinoma, regulatory mechanisms and opportunities for targeted therapy. Front. Oncol., 2022, 12, 852383. doi: 10.3389/fonc.2022.852383 PMID: 35392233
  11. Badoiu, S.C.; Greabu, M.; Miricescu, D.; Stanescu-Spinu, I.I.; Ilinca, R.; Balan, D.G.; Balcangiu-Stroescu, A.E.; Mihai, D.A.; Vacaroiu, I.A.; Stefani, C.; Jinga, V. PI3K/AKT/mTOR dysregulation and reprogramming metabolic pathways in renal cancer: Crosstalk with the VHL/HIF axis. Int. J. Mol. Sci., 2023, 24(9), 8391. doi: 10.3390/ijms24098391 PMID: 37176098
  12. Fu, W.; Wu, G. Targeting mTOR for anti-aging and anti-cancer therapy. Molecules, 2023, 28(7), 3157. doi: 10.3390/molecules28073157 PMID: 37049920
  13. Derwich, A.; Sykutera, M.; Bromińska, B.; Andrusiewicz, M.; Ruchała, M.; Sawicka-Gutaj, N. Clinical implications of mTOR expression in papillary thyroid cancer—A systematic review. Cancers, 2023, 15(6), 1665. doi: 10.3390/cancers15061665 PMID: 36980552
  14. Alves, C.L.; Ditzel, H.J. Drugging the PI3K/AKT/mTOR Pathway in ER+ breast cancer. Int. J. Mol. Sci., 2023, 24(5), 4522. doi: 10.3390/ijms24054522 PMID: 36901954
  15. Cerma, K.; Piacentini, F.; Moscetti, L.; Barbolini, M.; Canino, F.; Tornincasa, A.; Caggia, F.; Cerri, S.; Molinaro, A.; Dominici, M.; Omarini, C. Targeting PI3K/AKT/mTOR pathway in breast cancer: From biology to clinical challenges. Biomedicines, 2023, 11(1), 109. doi: 10.3390/biomedicines11010109 PMID: 36672617
  16. Li, Q.; Li, Z.; Luo, T.; Shi, H. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. Molecular Biomed., 2022, 3(1), 47. doi: 10.1186/s43556-022-00110-2 PMID: 36539659

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers